side effects include:
hemorrhage
bleeding
fever
abnormal liver function
pneumonia
sepsis
allergic skin reactions
heart failure
other hemorrhagic events
hemoperitoneum
hemoptysis
liver bleeding
lung bleeding
mouth bleeding
retroperitoneal bleeding
individual among patients
lepirudin
active ingredient
refludan
controlled trials
hemorrhagic events
serious side effects
use of lepirudin
following
controlled trials
bleeding from puncture sites
wounds
anemia
isolated drop in hemoglobin concentration
hematoma
unclassified hemorrhage
rectal bleeding
epistaxis
hemothorax
vaginal bleeding
intracranial bleeding
intracranial hemorrhage
ich
patients with acute myocardial infarction
thrombolytic therapy
lepirudin
overall prevalence of ich in this population
patients
ich
patients
concomitant thrombolytic therapy
case report of thrombocytopenia
serious anaphylactic reactions
shock
death
hypersensitivity reactions
patients
skin rashes
pruritus
urticaria
flushing
chills
airway reactions
cough
bronchospasm
stridor
dyspnea
anaphylaxis
anaphylactoid reactions
patients
suspected allergic reactions
patients
receiving
receiving thrombolytic therapy for acute myocardial infarction
contrast media for coronary angiography
antihirudin antibodies
heparin-induced thrombocytopenia patients
receiving lepirudin
active ingredient
refludan
complexation of lepirudin
antibodies
anticoagulant effect
delayed renal elimination of active complexes
lepirudin neutralization
allergic reactions
positive antibody tests
adverse reactions
following reexposure
mild skin reactions
respiratory effects as a result of hypersensitivity reactions
patients
symptoms
cough
bronchospasm
stridor
dyspnea
pneumonia
patients
control patients
abnormal elevations of liver transaminases
other measurements of liver function
patients
general
side effects
fever
patients
unspecified allergic reactions
patients
prevalence of sepsis
unspecified infections
multiorgan failure
control patients
cardiovascular
side effects
worsened heart failure
patients
pericardial effusion
ventricular fibrillation
patients
edema
tongue
laryngeal
angioedema
use of lepirudin
active ingredient
refludan
new
worsened renal insufficiency
patients
control patients
side effects of refludan
fda
healthcare professional for medical advice